Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PTEN dosage is essential for neurofibroma development and malignant transformation

21 Oct 2009

Abstract excerpt

Patients with neurofibromatosis type 1 (NF1) carry approximately a 10% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST). Although the molecular mechanisms underlying NF1 to MPNST malignant transformation remain unclear, alterations of both the RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways have been implicated. In a series of genetically engineered murine models, we perturbed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurofibromatosis and Schwannoma Cases
Share to Sarcoma Diagnosis and Treatment
Share to Soft tissue tumors and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19846776
DOI: 10.1073/pnas.0910398106

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PTEN dosage is essential for neurofibroma development and malignant transformationPMID 19846776Read ↗

PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.Semantic proximity Read ↗

Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.Semantic proximity Read ↗

Tumor Suppressor Mutations and Growth Factor Signaling in the Pathogenesis of NF1-Associated Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

Conditional Inactivation of<i>Pten</i>with<i>EGFR</i>Overexpression in Schwann Cells Models Sporadic MPNSTSemantic proximity Read ↗

MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesisSemantic proximity Read ↗

Malignancy in neurofibromatosis type 1.Semantic proximity Read ↗

RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.Semantic proximity Read ↗

How does the Schwann cell lineage form tumors in NF1?Semantic proximity Read ↗

Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

A genetic mouse model with postnatal <i>Nf1</i> and <i>p53</i> loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumorSemantic proximity Read ↗

FOXM1, MEK, and CDK4/6: New targets for MPNST therapySemantic proximity Read ↗

Genomic MET amplification occurs early in NF1-related malignant peripheral nerve sheath tumor (MPNST) progression and is a potent therapeutic targetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.